Our current findings confirm the importance of intact MHC-I expression on tumor cells for response to anti-PD-1 monotherapy and indicate that combination immunotherapy could overcome MHC-I downregulation or loss on tumor cells. The gene discussed is PDCD1; the disease is neoplasm.